Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay

McClellan M. Walther, Peter J. Kragel, Emile Trahan, David Venzon, Harry C. Blair, Paul H. Schlesinger, Carlos Jamai-Dow, M. Winnann Ewing, Charles E. Myers, W. Marston Linehan

Research output: Contribution to journalArticlepeer-review


The antineoplastic properties of suramin, a polyanionic agent with demonstrated antigrowth factor activity, are under evaluation in vitro, in vivo, and in clinical trials. Suramin has been shown to have antitumor activity in patients with advanced, hormone refractory prostate cancer. During these trials, significant resolution of osseous pain was observed in nearly three quarters of the patients treated with suramin. To evaluate the effect of suramin on bone cells, we studied the effect of suramin on bone resorption in a neonatal mouse calvarial assay. Suramin inhibited bone-resorbing activity in a dose-related fashion and had an additive effect with calcitonin. Calvaria pretreated with suramin had less bone-resorbing activity, fewer attached osteoblasts, and less medium alkaline phosphatase activity than control calvaria. Suramin also inhibited osteoclastic release of tritiated proline from labeled bone in a dose-dependent fashion. The effect of metastatic prostate carcinoma on bone is incompletely understood, but may be moderated by tumor-produced factors and/or cytokines. The effects of several such agents, therefore, were examined in combination with suramin. Bone resorption induced by PTH, epidermal growth factor, tumor necrosis factor, and a tumor-produced factor, PTH related-protein, was blocked by suramin. The ability of suramin to inhibit the bone-resorbing effects of several cytokines suggests that its mechanism may involve direct action on bone metabolism. Autoradiography performed on calvaria treated with labeled suramin demonstrated heavy deposition of suramin on the outer surface of the matrix, adjacent to osteoblasts and osteoclasts lining the outer table, suggesting that bone cells may be subject to high local concentrations of the drug, in keeping with this hypothesis.

Original languageEnglish
Pages (from-to)2263-2270
Number of pages8
Issue number5
StatePublished - Nov 1992


Dive into the research topics of 'Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay'. Together they form a unique fingerprint.

Cite this